Olumiant generics — when can they launch?
Olumiant (baricitinib) · Eli Lilly · 17 active US patents · 0 expired
Where Olumiant sits in the generic timeline
Imminent generic cliff: earliest active US patent for Olumiant expires in 2029 (~3 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 14 patents
- Composition of Matter — 3 patents
FDA U-codes carved out by Olumiant patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-247 | (no description) |
U-3500 | (no description) |
U-3372 | (no description) |
Sample patent estate
Showing 6 of 17 active US patents. View full estate on the Olumiant drug page →
-
This patent protects azetidine and cyclobutane derivatives as JAK inhibitors for treating JAK-associated diseases, including inflammatory and autoimmune disorders, and cancer.USPTO title: Azetidine and cyclobutane derivatives as JAK inhibitors
-
This patent protects azetidine and cyclobutane derivatives as JAK inhibitors for treating JAK-associated diseases, including inflammatory and autoimmune disorders, and cancer.USPTO title: Azetidine and cyclobutane derivatives as JAK inhibitors
-
This patent protects methods for treating hair loss disorders by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.USPTO title: Methods for treating hair loss disorders
-
This patent protects methods for treating hair loss disorders by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.USPTO title: Methods for treating hair loss disorders
-
This patent protects methods for treating hair loss disorders by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.USPTO title: Methods for treating hair loss disorders
-
This patent protects methods for treating hair loss disorders by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.USPTO title: Methods for treating hair loss disorders
Sources
- FDA Orange Book — patents listed against Olumiant (NDA filed 2018)
- Olumiant drug profile — full patent estate, indications, clinical trials, pricing
- Eli Lilly patent portfolio
- Patent cliff 2029 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Olumiant — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →